Founded in 1920, Endo International plc is a specialty pharmaceutical company with global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. The company has historically focused on developing, manufacturing, and marketing quality branded and generic pharmaceutical products across key therapeutic areas including pain management, urology, and oncology.
Endo's product portfolio includes widely recognized medications such as Percocet, along with numerous generic and branded specialty pharmaceuticals. The company operates through multiple business segments and has grown through strategic acquisitions, including the purchase of American Medical Systems in 2011 and Par Pharmaceutical in 2015. In a significant corporate development, Endo merged with Mallinckrodt Pharmaceuticals on July 31, 2025, creating a combined entity that subsequently divided into two independent companies: Par Health, focusing on generics and sterile injectables, and Keenova Therapeutics, concentrating on specialty therapeutics.
